F-star Biotechnology Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From F-star Biotechnology Limited
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.
- Drug Discovery Tools
- Other Names / Subsidiaries
- F-star Alpha Ltd.
- F-star GmbH
- F-star Therapeutics